Summary & Overview
HCPCS J7669: Metaproterenol Sulfate Inhalation Solution, Unit Dose
HCPCS Level II code J7669 represents metaproterenol sulfate inhalation solution, an FDA-approved, non-compounded unit-dose bronchodilator supplied for administration through durable medical equipment (DME). This medication code is relevant for billing of nebulized bronchodilator therapy when the supplier furnishes the unit-dose solution for use with a nebulizer. Nationally, the code matters for payers and providers managing outpatient and home-based respiratory therapies, particularly for patients with obstructive airway diseases requiring inhalation treatments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context of the product, typical sites of service where the code applies, and what to expect in terms of billing categories and service line placement. The publication outlines benchmarking and coverage considerations where available, summarizes relevant policy and reimbursement themes affecting DME-delivered inhalation medications, and provides operational context for coding and claim submission. Data not available in the input for specific reimbursement rates, payer-specific policy text, associated taxonomies, and ICD-10 pairings.
Billing Code Overview
HCPCS Level II code J7669 describes metaproterenol sulfate, inhalation solution, an FDA-approved final product provided in unit dose form (per 10 milligrams) and intended for administration through durable medical equipment (DME). The entry denotes a prescription respiratory medication furnished as a ready-to-use inhalation solution for patients requiring nebulized bronchodilator therapy.
Service Type: Respiratory inhalation medication administered via DME
Typical Site of Service: Home or outpatient settings where DME nebulizer administration is provided, including patient residence when DME is used and outpatient clinics that supply DME-administered inhalation treatments.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with chronic obstructive pulmonary disease (COPD) and recurrent bronchospasm presents to a durable medical equipment (DME) provider for medication delivery and inhalation therapy support. The prescriber orders J7669 (metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 milligrams) to be supplied with the patient’s nebulizer device. Clinical workflow: the prescriber documents the diagnosis and medical necessity in the chart, writes an order for the unit-dose inhalation solution, and forwards the prescription to the DME supplier. The DME supplier verifies patient eligibility and coverage, confirms device compatibility, prepares the unit-dose packs, and arranges shipment or in-person delivery. Education on administration, storage, and adverse effects is provided by a respiratory therapist or DME clinician at delivery. Claims submission uses J7669 for the medication supply line; any required service or delivery charges are billed separately per payer rules. Authorization or prior approval may be obtained from the patient’s payer when required; common payers include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service |